Seres Therapeutics director Hans Woerle resigns
Seres Therapeutics, Inc. reported a governance change with the resignation of board member Hans-Juergen Woerle, M.D., Ph.D.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Seres Therapeutics, Inc. reported a governance change with the resignation of board member Hans-Juergen Woerle, M.D., Ph.D. On May 30, 2026, he notified the company that he would step down from the board and its committees, effective May 31, 2026. The company states that his departure is not due to any disagreement regarding operations, policies, or practices.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board resignation notification date: May 30, 2026
Board resignation effective date: May 31, 2026
Trading symbol: MCRB
+1 more
4 metrics
Board resignation notification date
May 30, 2026
Date Hans-Juergen Woerle informed the company
Board resignation effective date
May 31, 2026
Effective date of Woerle’s departure from board and committees
Trading symbol
MCRB
Common stock listed on Nasdaq Global Select Market
Company phone number
(617) 945-9626
Registrant’s telephone number
Key Terms
board of directors, Nasdaq Global Select Market, emerging growth company, principal executive offices
4 terms
board of directors financial
"resigned from his position as a member of the board of directors of Seres Therapeutics, Inc."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Nasdaq Global Select Market financial
"The Nasdaq Stock Market LLC (Nasdaq Global Select Market)"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
principal executive offices financial
"Address of principal executive offices"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Seres Therapeutics (MCRB) disclose in this 8-K?
Seres Therapeutics disclosed that Hans-Juergen Woerle, M.D., Ph.D. resigned from its board of directors and the committees on which he served, effective May 31, 2026. The company states his resignation is not due to any disagreement with its operations, policies, or practices.
When is Hans-Juergen Woerle’s resignation from Seres Therapeutics’ board effective?
Hans-Juergen Woerle’s resignation is effective May 31, 2026. He informed Seres Therapeutics of his decision on May 30, 2026, and the 8-K notes that he is also stepping down from the board committees on which he served.
Did Seres Therapeutics report any disagreement linked to Woerle’s resignation?
Seres Therapeutics stated that Hans-Juergen Woerle’s resignation is not due to any disagreement with the company. The filing specifies there is no disagreement regarding the company’s operations, policies, or practices related to his departure from the board.
What role did Hans-Juergen Woerle hold at Seres Therapeutics before resigning?
Hans-Juergen Woerle served as a member of the board of directors of Seres Therapeutics, Inc. The filing also notes that he sat on certain board committees, from which he will resign effective May 31, 2026, along with his board role.
Who signed the Seres Therapeutics 8-K announcing the board resignation?
The 8-K was signed on behalf of Seres Therapeutics by Thomas J. DesRosier. He is identified in the filing as Chief Legal Officer and Executive Vice President, and he signed the report dated June 1, 2026, for the company.
On which exchange is Seres Therapeutics (MCRB) listed according to the filing?
Seres Therapeutics’ common stock, trading under the symbol MCRB, is listed on The Nasdaq Stock Market LLC. The filing specifies the Nasdaq Global Select Market as the exchange for the company’s common stock with a par value of $0.001 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates